HHSN261201400038C;SBIR TOPIC 326 DEVELOPMENT OF NOVEL THERAPEUTIC AGENTS THAT TARGET CANCER STEM CELLS;PROJECT TITLE: CROSSING THE BBB AND TARGETING CSCS FOR GBM THERAPY;CONTRACT PERFORMANCE PERIOD 09
$222,900N43FY2014CANIH
Synergene Therapeutics, Inc., Washington DC
Investigators
Abstract
Crossing the BBB and Targeting the CSCs for GBM Therapy
View original record on NIH RePORTER →